Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8521631 | 0.98 | KCNH2 (0.48) | KCNH2NOS2PDPK1BACE1PI4KA | |
| SCHEMBL27681192 | 0.98 | KCNH2 (0.48) | KCNH2NOS2PDPK1BACE1PI4KA | |
| SCHEMBL27661521 | 0.98 | KCNH2 (0.48) | KCNH2NOS2PDPK1BACE1PI4KA | |
| SCHEMBL18794910 | 0.98 | KCNH2 (0.48) | KCNH2NOS2PDPK1BACE1PI4KA | |
| Hydrochloric Acid SCHEMBL12821604 | 0.96 | KCNH2 (0.47) | KCNH2NOS2PDPK1BACE1PI4KA | |
| SCHEMBL5924367 | 0.94 | NOS2 (0.46) | KCNH2NOS2PDPK1BACE1TLR8 | |
| SCHEMBL16579802 | 0.90 | BACE1 (0.33) | KCNH2NOS2PDPK1BACE1 | |
| SCHEMBL23812481 | 0.89 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL5924432 | 0.86 | — | — | |
| SCHEMBL12559910 | 0.82 | HRH3 (0.40) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368517-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | UNIV LEUVEN KATH (BE) | 2023-07-05 | — | — | EP | disclosed |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | CURZA GLOBAL, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3119394-B1 | COMPOSITIONS AND METHODS COMPRISING 2-(ACYLAMINO)IMIDAZOLES | CURZA GLOBAL LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-10-20 | — | — | US | disclosed |
| EP-3601232-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | Curza Global LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10493061-B2 | Compositions and methods comprising 2-(acylamino)imidazoles | CURZA GLOBAL, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2018-10-25 | — | — | US | disclosed |
| WO-2018184019-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | CURZA GLOBAL, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-3368517-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven (BE) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017070755-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-05-04 | — | — | WO | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| WO-2008043533-A3 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | BAYER HEALTHCARE AG (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008043533-A2 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005097113-A2 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-6087361-A | TREATING ELEVATED INTRAOCULAR PRESSURE, NASAL CONGESTION AND DIARRHEA IN A MAMMAL; NO SIDE EFFECT OF BLOOD PRESSURE | ALLERGAN SALES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0828491-A1 | ARYL-IMIDAZOLINES AND ARYL-IMIDAZOLES USEFUL AS ALPHA-2 ADRENERGIC AGONISTS WITHOUT CARDIOVASCULAR SIDE EFFECTS | Allergan (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996035424-A1 | ARYL-IMIDAZOLINES AND ARYL-IMIDAZOLES USEFUL AS ALPHA-2 ADRENERGIC AGONISTS WITHOUT CARDIOVASCULAR SIDE EFFECTS | ALLERGAN (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | KCNH2 567/4885NOS2 1786/4885PDPK1 3757/4885 |
| US-10493061-B2 | Compositions and methods comprising 2-(acylamino)imidazoles | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC6 | KCNH2 1072/4885NOS2 1007/4885PDPK1 2714/4885 |
| US-20180305321-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | AADAC, TYR, HAAO | KCNH2 3327/4885NOS2 889/4885PDPK1 3262/4885 |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KCNH2 2008/4885NOS2 1930/4885PDPK1 1822/4885 |
| US-10807960-B2 | Compounds, compositions, and methods for controlling biofilms | AADAC, TYR, HAAO | KCNH2 3327/4885NOS2 889/4885PDPK1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.